Myricx Bio: Funding, Investors & Team (Sep 2026)
Myricx Bio is a company specializing in discovering small molecule drugs, specifically inhibitors of N-myristoyl transferase (NMT), which is crucial for cancer cell survival. They are primarily focused on oncology but are also looking at other potential uses for their proprietary inhibitors. Myricx Bio is developing a pipeline of ADCs that use their NMT inhibitor as a payload, showing promising results in preclinical studies for various solid tumors and cancer cell types.
Myricx Bio has raised $115M across 1 funding round on record, the most recent a Series A of $115M announced in Jul 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Myricx Bio Company Profile and Key Stats
Latest funding round on record: Jul 2024.
Myricx Bio Funding Rounds
Myricx Bio Founders and Leadership Team
Contact details for the Myricx Bio team: 1 of 1 has an email address on file.
Start 14-day free trial →Myricx Bio Funding Compared to Other Biotechnology Startups
Myricx Bio's latest round of $115M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Myricx Bio in Biotechnology and London
Companies Similar to Myricx Bio
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Myricx Bio Funding FAQs
What does Myricx Bio do?
Myricx Bio is a company specializing in discovering small molecule drugs, specifically inhibitors of N-myristoyl transferase (NMT), which is crucial for cancer cell survival. They are primarily focused on oncology but are also looking at other potential uses for their proprietary inhibitors. Myricx Bio is developing a pipeline of ADCs that use their NMT inhibitor as a payload, showing promising results in preclinical studies for various solid tumors and cancer cell types.
How much funding has Myricx Bio raised?
Myricx Bio has raised $115M across 1 round on record. The most recent is a Series A of $115M announced in Jul 2024.
When did Myricx Bio last raise funding?
Myricx Bio's most recent funding round on record is a Series A of $115M, announced in Jul 2024.
Who founded Myricx Bio?
FundedIQ lists Ed Tate (Founder) at Myricx Bio.
Where is Myricx Bio headquartered?
Myricx Bio is based in London, England, United Kingdom.
How many employees does Myricx Bio have?
Myricx Bio is in the 1-10 employee band.
How does Myricx Bio's funding compare to other Biotechnology startups?
Myricx Bio's latest round of $115M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Myricx Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Myricx Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.